EARS - Auris Medical Holding Ltd.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.3128
-0.0062 (-1.94%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close0.3190
Open0.3110
Bid0.3000 x 800
Ask0.3400 x 3100
Day's Range0.3000 - 0.3199
52 Week Range0.2300 - 2.4500
Volume455,441
Avg. Volume1,330,551
Market Cap11.729M
Beta (3Y Monthly)-1.31
PE Ratio (TTM)N/A
EPS (TTM)-1.3270
Earnings DateNov 8, 2017 - Nov 13, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.47
Trade prices are not sourced from all markets
  • Benzinga3 days ago

    Buyer's Remorse? OTC Stock Zoom Technologies Zooms Higher Amid Potential Buyer Confusion

    Zoom Technologies Inc (OTC: ZOOM ) traded higher by as much as 120 percent Thursday morning after popular video and audio platform Zoom Video Communications Inc (NASDAQ: ZM ) held its highly anticipated ...

  • GlobeNewswire6 days ago

    Auris Medical Receives Positive Nasdaq Listing Determination

    Auris Medical Holding Ltd. (EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders, today announced that the Nasdaq Hearings Panel (the ''Panel'') has granted the Company’s request for the continued listing of the Company’s securities on The Nasdaq Capital Market (“Nasdaq”). The Company’s continued listing on Nasdaq is subject to the Company evidencing compliance with the minimum $1.00 bid price requirement on or before August 5, 2019. At the hearing before the Panel, the Company presented its plan to regain compliance with the minimum bid price requirement, including the implementation of a reverse stock split if necessary.

  • GlobeNewswire23 days ago

    Auris Medical Announces Randomization of First Dose Cohort in AM-201 Phase 1b Proof-of-Concept Study

    Auris Medical Holding Ltd. (EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders, today announced that the first cohort of subjects have been randomized in its Phase 1b proof-of-concept trial of AM-201, the Company's investigational drug for the prevention of antipsychotic-induced weight gain and somnolence. The Phase 1b trial with AM-201 is being conducted at one European site. The trial will enroll in total 50 healthy volunteers who will receive either AM-201 or placebo concomitantly with the antipsychotic drug olanzapine over four weeks.

  • GlobeNewswirelast month

    Auris Medical Announces 20-F Filing

    March 14, 2019 - Auris Medical Holding AG (EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders, announced today that it has filed its Annual Report on Form 20-F for the year ended December 31, 2018, with the U.S. Securities and Exchange Commission. Upon request, Auris Medical will send a copy of the Annual Report to any requesting shareholder. Auris Medical is a Swiss biopharmaceutical company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders.

  • ACCESSWIRElast month

    These Four Healthcare Stocks Could Test March Highs

    Given that the success of the healthcare industry is dependent on companies meeting the demands of patients who simply want to live healthy lives, any company taking a patient-centric focus to their healthcare framework has seen impressive gains in the first few months of 2019. Investors looking for potential opportunities could benefit from keeping tabs on the healthcare industry. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Hancock Jaffe Laboratories Inc (HJLI), Kitov Pharmaceuticals Ltd (KTOV), and Auris Medical Holding AG (EARS) are 4 healthcare companies heating up on Thursday.

  • Associated Presslast month

    Auris: 4Q Earnings Snapshot

    On a per-share basis, the Zug, Switzerland-based company said it had a loss of 12 cents. For the year, the company reported that its loss narrowed to $11.8 million, or 74 cents per share. The company's ...

  • GlobeNewswirelast month

    Auris Medical Provides Business Update and Reports Fourth Quarter and Full Year 2018 Financial Results

    Phase 1 trial confirmed superior bioavailability of intranasal betahistine as well as good safety and tolerability Intranasal betahistine program progressing towards.

  • GlobeNewswirelast month

    Auris Medical Announces Publication of AM-111 Phase 3 Results in Peer-Reviewed Scientific Journal

    Auris Medical Holding AG (EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders, today announced the publication of an article that presents and discusses in detail the outcomes from the HEALOS Phase 3 trial with AM-111, Auris Medical's investigational treatment for acute inner ear hearing loss. The peer-reviewed article "Efficacy and Safety of AM-111 in the Treatment of Acute Unilateral Sudden Deafness - A Double-Blind, Randomized, Placebo-Controlled Phase 3 Study" was published in Otology & Neurotology, one of the leading journals in the field of scientific and clinical inner ear research. "The HEALOS trial demonstrated that effective hearing protection is possible with a drug-based approach even in the case of profound acute hearing loss, a condition with very poor prognosis for recovery and high risk for life-long auditory and cognitive disability," commented Hinrich Staecker, MD, PhD, Professor, Department of Otolaryngology Head and Neck Surgery, University of Kansas Medical Center, Kansas City, lead author on the publication.

  • GlobeNewswirelast month

    Auris Medical to Report Fourth Quarter and Full Year 2018 Financial Results and Provide Business Update on Thursday, March 14, 2019

    Zug, Switzerland, March 07, 2019 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical.

  • GlobeNewswire2 months ago

    Auris Medical Announces Receipt of Nasdaq Notice

    Auris Medical Holding AG (EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders, today announced its receipt of notice from The Nasdaq Stock Market LLC ("Nasdaq") indicating that the Company did not meet Nasdaq's January 28, 2019 deadline to regain compliance with Nasdaq Listing Rule 5550(a)(2) due to the bid price per share for its common shares remaining below $1.00. Further, Nasdaq determined that the Company was not eligible for a second 180 day period to regain compliance since the Company did not comply with the $5,000,000 Stockholders' Equity initial listing requirement for The Nasdaq Capital Market. The Notice states that, unless the Company requests an appeal, Nasdaq intends to suspend the Company's common shares and remove them from listing and registration on Nasdaq.

  • GlobeNewswire3 months ago

    Auris Medical Announces Full Repayment of Hercules Loan Facility

    On July 19, 2016, the Company had entered into a loan and security agreement with Hercules Technology Growth Capital, Inc. ("Hercules") and drawn $12.5 million under the facility. On January 31, 2019, the Company made the final payment to Hercules under the facility, comprising the last amortization rate as well as an end of term charge, 12 months ahead of the original schedule. With the final payment, all covenants and collaterals in favor of Hercules have been lifted.

  • GlobeNewswire3 months ago

    Auris Medical to Redomicile Holding Company from Switzerland to Bermuda

    Auris Medical Holding AG (EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders, today announced its intention to relocate the Company's domicile from Zug, Switzerland to Hamilton, Bermuda. With the redomiciliation, the Company expects to gain more corporate flexibility, achieve cost savings and operate under a jurisdiction that is more familiar to U.S. investors.

  • ACCESSWIRE3 months ago

    4 Healthcare Stocks Making Moves On Wednesday (1/23/19)

    CORAL GABLES, FL / ACCESSWIRE / January 23, 2019 / The future of healthcare stocks, and the medical sector industry as a whole, is solely dependent on the ability of medical experts and healthcare professionals to work to provide the best quality of care for patients in the space. With the rise of global population, coupled with depletion of most common resources, consumer access to healthcare is crucial to securing the health and wellness of all living people, resulting in a need for companies in the space to meet these demands. As companies in the healthcare industry work to better understand the needs of their patients, the sector, in its entirety, may boast impressive opportunities for investors looking to the space.

  • GlobeNewswire3 months ago

    Auris Medical Announces Publication of New Data Highlighting the Role of Betahistine in Promoting the Restoration of Forgotten Memories in Mice and Healthy Volunteers

    Auris Medical Holding AG (EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders, today highlighted the advance publication of an article demonstrating that betahistine promotes the retrieval of forgotten memories in mice and in healthy human volunteers. The article was written by an independent Japanese research group and presents the outcomes of a study on the role of histamine in the recollection of forgotten memories and the effects of using histamine H3 receptor inverse agonists for treatment. In the first part of the study, the authors demonstrated in mice that treatment with betahistine or thioperamide induced the recall of forgotten memories of certain objects one week or one month later.

  • GlobeNewswire3 months ago

    Auris Medical Provides Update on Intranasal Betahistine Programs

    Auris Medical Holding AG (EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and CNS disorders, today provided an update on its intranasal betahistine development programs. In December 2018, the Company announced the acquisition of an Orphan Drug Designation for betahistine in the treatment of obesity associated with Prader-Willi syndrome (PWS).

  • ACCESSWIRE4 months ago

    New Healthcare Trends Pushing Stocks Higher On Thursday

    CORAL GABLES, FL / ACCESSWIRE / December 6, 2018 / Analyst firms like Global Market Insights are expecting a lot as far as the future of healthcare is concerned. The firm reports that the healthcare industry ...

  • GlobeNewswire4 months ago

    Auris Medical Announces Acquisition of Orphan Drug Designation and Secures Rights to In-License Additional Patents Related to Betahistine

    Auris Medical Holding AG (EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and mental health supportive care, today announced a strategic expansion for its intranasal betahistine development program. In two related transactions, the Company has acquired an Orphan Drug Designation for betahistine in the treatment of obesity associated with Prader-Willi syndrome (PWS) and signed a binding letter of intent to in-license exclusive rights to two US Patents relating to the use of betahistine for the treatment of depression and attention-deficit / hyperactivity disorder (ADHD), respectively.

  • ACCESSWIRE5 months ago

    Biotech and Cannabis Stocks to Watch

    With Thanksgiving behind us here's a few biotech/ healthcare companies that might be worth looking at before after your meal HENDERSON, NV / ACCESSWIRE / November 26, 2018 / Today we are highlighting: ...

  • GlobeNewswire5 months ago

    Detailed Research: Economic Perspectives on Wingstop, Marlin Business Services, Aware, Zynerba Pharmaceuticals, Auris Medical Holding AG, and Gulf Island Fabrication — What Drives Growth in Today's Competitive Landscape

    NEW YORK, Nov. 23, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • ACCESSWIRE5 months ago

    Today's Research Reports on Trending Tickers: Auris Medical and Bioblast Pharma

    NEW YORK, NY / ACCESSWIRE / November 21, 2018 / It was a day of gains for biotech stocks Auris Medical Holding and Bioblast Pharma after the companies announced positive developments. Bioblast announced it has executed a definitive agreement to acquire Enlivex Therapeutics while Auris Medical announced the results of a Pre-IND meeting with the FDA. Auris Medical Holding AG shares were up nearly 36% on Tuesday on roughly 13.7 million shares traded.

  • GlobeNewswire5 months ago

    Auris Medical Announces Results of Pre-IND Meeting With FDA For AM-201 Program in Olanzapine-Induced Weight Gain

    Auris Medical Holding AG (EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and mental health supportive care, today announced the results of its pre-Investigational New Drug (pre-IND) meeting with the United States Food & Drug Administration (FDA), where the FDA addressed the Company's questions and provided guidance on its AM-201 program with intranasal betahistine for the prevention of olanzapine-induced weight gain. In its written response, the FDA supported the planned conduct of a multiple dose Phase 1 trial with AM-201 administered to healthy subjects in combination with olanzapine to evaluate the pharmacokinetics, pharmacodynamics, and safety, and to establish proof-of-concept.

  • Associated Press5 months ago

    Auris: 3Q Earnings Snapshot

    On a per-share basis, the Zug, Switzerland-based company said it had a loss of 14 cents. The company's shares closed at 63 cents. A year ago, they were trading at $7.39. _____ This story was generated ...

  • GlobeNewswire5 months ago

    Auris Medical Reports Third Quarter 2018 Financial Results and Provides Business Update

    Positive outcomes from second Phase 1 trial with intranasal betahistine Further evidence for betahistine's preventive effects in antipsychotic-induced weight gain.

  • GlobeNewswire5 months ago

    Auris Medical to Report Third Quarter 2018 Financial Results and Provide Business Update on Thursday, November 15, 2018

    Zug, Switzerland, November 08, 2018 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical.